Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 338

1.

Body mass index in acute heart failure: association with clinical profile, therapeutic management and in-hospital outcome.

Parissis J, Farmakis D, Kadoglou N, Ikonomidis I, Fountoulaki E, Hatziagelaki E, Deftereos S, Follath F, Mebazaa A, Lekakis J, Filippatos G.

Eur J Heart Fail. 2016 Mar;18(3):298-305. doi: 10.1002/ejhf.489. Epub 2016 Jan 28.

2.

[Cardiovascular drugs in aged and multimorbid patients].

Follath F.

Praxis (Bern 1994). 2015 Sep 16;104(19):997-1000; quiz 1001-2. doi: 10.1024/1661-8157/a002139. German.

PMID:
26373905
3.

Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity.

Parissis JT, Andreoli C, Kadoglou N, Ikonomidis I, Farmakis D, Dimopoulou I, Iliodromitis E, Anastasiou-Nana M, Lainscak M, Ambrosio G, Mebazaa A, Filippatos G, Follath F.

Clin Res Cardiol. 2014 Sep;103(9):733-41. doi: 10.1007/s00392-014-0708-0. Epub 2014 Apr 10.

PMID:
24718849
4.

Prognostic impact of systemic inflammatory diseases in elderly patients with congestive heart failure.

Burkard T, Pfister O, Rickli H, Follath F, Hack D, Zaker R, Pittl U, Handschin R, Pfisterer M, Brunner-La Rocca HP; Time-CHF Investigators.

QJM. 2014 Feb;107(2):131-8. doi: 10.1093/qjmed/hct205. Epub 2013 Oct 15.

5.

Gender-related differences in patients with acute heart failure: management and predictors of in-hospital mortality.

Parissis JT, Mantziari L, Kaldoglou N, Ikonomidis I, Nikolaou M, Mebazaa A, Altenberger J, Delgado J, Vilas-Boas F, Paraskevaidis I, Anastasiou-Nana M, Follath F.

Int J Cardiol. 2013 Sep 20;168(1):185-9. doi: 10.1016/j.ijcard.2012.09.096. Epub 2012 Oct 4.

PMID:
23041090
6.

Why and how do elderly patients with heart failure die? Insights from the TIME-CHF study.

Rickenbacher P, Pfisterer M, Burkard T, Kiowski W, Follath F, Burckhardt D, Schindler R, Brunner-La Rocca HP; TIME-CHF Investigators.

Eur J Heart Fail. 2012 Nov;14(11):1218-29. doi: 10.1093/eurjhf/hfs113. Epub 2012 Jul 6.

7.

Acute heart failure in patients with diabetes mellitus: clinical characteristics and predictors of in-hospital mortality.

Parissis JT, Rafouli-Stergiou P, Mebazaa A, Ikonomidis I, Bistola V, Nikolaou M, Meas T, Delgado J, Vilas-Boas F, Paraskevaidis I, Anastasiou-Nana M, Follath F.

Int J Cardiol. 2012 May 17;157(1):108-13. doi: 10.1016/j.ijcard.2011.11.098. Epub 2011 Dec 15.

PMID:
22178056
8.

Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis.

Yilmaz MB, Gayat E, Salem R, Lassus J, Nikolaou M, Laribi S, Parissis J, Follath F, Peacock WF, Mebazaa A.

Eur J Heart Fail. 2011 Nov;13(11):1244-52. doi: 10.1093/eurjhf/hfr121.

9.

Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan.

Papp Z, Édes I, Fruhwald S, De Hert SG, Salmenperä M, Leppikangas H, Mebazaa A, Landoni G, Grossini E, Caimmi P, Morelli A, Guarracino F, Schwinger RH, Meyer S, Algotsson L, Wikström BG, Jörgensen K, Filippatos G, Parissis JT, González MJ, Parkhomenko A, Yilmaz MB, Kivikko M, Pollesello P, Follath F.

Int J Cardiol. 2012 Aug 23;159(2):82-7. doi: 10.1016/j.ijcard.2011.07.022. Epub 2011 Jul 23. Review.

PMID:
21784540
10.

Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial.

Funck-Brentano C, van Veldhuisen DJ, van de Ven LL, Follath F, Goulder M, Willenheimer R; CIBIS-III investigators.

Eur J Heart Fail. 2011 Jul;13(7):765-72. doi: 10.1093/eurjhf/hfr051. Epub 2011 May 6.

11.

The role of β-blockers in the management of hypertension: an Asian perspective.

Tomlinson B, Dalal JJ, Huang J, Low LP, Park CG, Rahman AR, Reyes EB, Soenarta AA, Heagerty A, Follath F.

Curr Med Res Opin. 2011 May;27(5):1021-33. doi: 10.1185/03007995.2011.562884. Epub 2011 Mar 16. Review.

PMID:
21410302
12.

Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II).

Gallanagh S, Castagno D, Wilson B, Erdmann E, Zannad F, Remme WJ, Lopez-Sendon JL, Lechat P, Follath F, Höglund C, Mareev V, Sadowski Z, Seabra-Gomes RJ, Dargie HJ, McMurray JJ.

Cardiovasc Drugs Ther. 2011 Feb;25(1):77-85. doi: 10.1007/s10557-011-6284-x.

13.

Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF).

Follath F, Yilmaz MB, Delgado JF, Parissis JT, Porcher R, Gayat E, Burrows N, McLean A, Vilas-Boas F, Mebazaa A.

Intensive Care Med. 2011 Apr;37(4):619-26. doi: 10.1007/s00134-010-2113-0. Epub 2011 Jan 6.

14.

Clinical characteristics and predictors of in-hospital mortality in acute heart failure with preserved left ventricular ejection fraction.

Parissis JT, Ikonomidis I, Rafouli-Stergiou P, Mebazaa A, Delgado J, Farmakis D, Vilas-Boas F, Paraskevaidis I, Anastasiou-Nana M, Follath F.

Am J Cardiol. 2011 Jan;107(1):79-84. doi: 10.1016/j.amjcard.2010.08.044.

PMID:
21146691
15.

The impact of infections on critically ill acute heart failure patients: an observational study.

Rudiger A, Streit M, Businger F, Schmid ER, Follath F, Maggiorini M.

Swiss Med Wkly. 2010 Nov 18;140:w13125. doi: 10.4414/smw.2010.13125. eCollection 2010.

16.

Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods.

Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV, Delgado JF, Follath F.

Intensive Care Med. 2011 Feb;37(2):290-301. doi: 10.1007/s00134-010-2073-4. Epub 2010 Nov 18.

PMID:
21086112
17.

Acute pulmonary oedema: clinical characteristics, prognostic factors, and in-hospital management.

Parissis JT, Nikolaou M, Mebazaa A, Ikonomidis I, Delgado J, Vilas-Boas F, Paraskevaidis I, Mc Lean A, Kremastinos D, Follath F.

Eur J Heart Fail. 2010 Nov;12(11):1193-202. doi: 10.1093/eurjhf/hfq138. Epub 2010 Sep 13.

18.

Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial.

Krum H, van Veldhuisen DJ, Funck-Brentano C, Vanoli E, Silke B, Erdmann E, Follath F, Ponikowski P, Goulder M, Meyer W, Lechat P, Willenheimer R; behalf of the CIBIS III Investigators.

Cardiovasc Ther. 2011 Apr;29(2):89-98. doi: 10.1111/j.1755-5922.2010.00185.x.

PMID:
20528880
19.

Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery.

Mebazaa A, Pitsis AA, Rudiger A, Toller W, Longrois D, Ricksten SE, Bobek I, De Hert S, Wieselthaler G, Schirmer U, von Segesser LK, Sander M, Poldermans D, Ranucci M, Karpati PC, Wouters P, Seeberger M, Schmid ER, Weder W, Follath F.

Crit Care. 2010;14(2):201. doi: 10.1186/cc8153. Epub 2010 Apr 28. Review.

20.

Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial.

Castagno D, Jhund PS, McMurray JJ, Lewsey JD, Erdmann E, Zannad F, Remme WJ, Lopez-Sendon JL, Lechat P, Follath F, Höglund C, Mareev V, Sadowski Z, Seabra-Gomes RJ, Dargie HJ.

Eur J Heart Fail. 2010 Jun;12(6):607-16. doi: 10.1093/eurjhf/hfq038. Epub 2010 Mar 30.

21.

Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine.

Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G; European Society of Cardiology; European Society of Intensive Care Medicine.

Eur J Heart Fail. 2010 May;12(5):423-33. doi: 10.1093/eurjhf/hfq045. Epub 2010 Mar 30. Review.

22.

Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure.

Harjola VP, Follath F, Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Hochadel M, Komajda M, Lopez-Sendon JL, Ponikowski P, Tavazzi L.

Eur J Heart Fail. 2010 Mar;12(3):239-48. doi: 10.1093/eurjhf/hfq002.

23.

Challenging the dogma of high target doses in the treatment of heart failure: is more always better?

Follath F.

Arch Cardiovasc Dis. 2009 Nov;102(11):785-9. doi: 10.1016/j.acvd.2009.08.011. Epub 2009 Nov 13. Review.

24.
25.

Ethical considerations in cardiovascular prevention.

Follath F.

Fundam Clin Pharmacol. 2009 Dec;23(6):669-73. doi: 10.1111/j.1472-8206.2009.00695.x. Epub 2009 Jun 4. Review.

PMID:
19500153
26.

Presentation and outcome of critically ill medical and cardiac-surgery patients with acute heart failure.

Rudiger A, Businger F, Streit M, Schmid ER, Maggiorini M, Follath F.

Swiss Med Wkly. 2009 Feb 21;139(7-8):110-6. doi: smw-12446.

27.

Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II.

Komajda M, Hanon O, Hochadel M, Lopez-Sendon JL, Follath F, Ponikowski P, Harjola VP, Drexler H, Dickstein K, Tavazzi L, Nieminen M.

Eur Heart J. 2009 Feb;30(4):478-86. doi: 10.1093/eurheartj/ehn539. Epub 2008 Dec 23.

28.

Amiodarone inhibits arterial thrombus formation and tissue factor translation.

Breitenstein A, Stämpfli SF, Camici GG, Akhmedov A, Ha HR, Follath F, Bogdanova A, Lüscher TF, Tanner FC.

Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2231-8. doi: 10.1161/ATVBAHA.108.171272. Epub 2008 Oct 30.

PMID:
18974383
29.

[Heart failure in men and women: important differences in the diagnostic workup and treatment].

Lenzen MJ, Rosengren A, Scholte op Reimer WJ, Follath F, Boersma E, M L S, Cleland JG, Komajda M.

Ned Tijdschr Geneeskd. 2008 Oct 4;152(40):2182-5. Dutch.

PMID:
18953781
30.

Predictors of short term mortality in heart failure - insights from the Euro Heart Failure survey.

Velavan P, Khan NK, Goode K, Rigby AS, Loh PH, Komajda M, Follath F, Swedberg K, Madeira H, Cleland JG.

Int J Cardiol. 2010 Jan 7;138(1):63-9. doi: 10.1016/j.ijcard.2008.08.004. Epub 2008 Sep 11.

PMID:
18789548
31.

Serological evidence for the association of Bartonella henselae infection with arrhythmogenic right ventricular cardiomyopathy.

H Fischer A, van der Loo B, M Shär G, Zbinden R, Duru F, Brunckhorst C, Rousson V, Delacrétaz Y E, Stuber T, Oechslin EN, Follath F, Jenni R.

Clin Cardiol. 2008 Oct;31(10):469-71. doi: 10.1002/clc.20269.

32.

Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial.

Düngen HD, Apostolović S, Inkrot S, Tahirović E, Krackhardt F, Pavlović M, Putniković B, Lainscak M, Gelbrich G, Edelmann F, Wachter R, Eschenhagen T, Waagstein F, Follath F, Rauchhaus M, Haverkamp W, Osterziel KJ, Dietz R; CIBIS-ELD Investigators, Subproject Multicenter Trials in the Competence Network Heart Failure.

Clin Res Cardiol. 2008 Sep;97(9):578-86. doi: 10.1007/s00392-008-0681-6. Epub 2008 Jun 9.

PMID:
18542839
33.

New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey.

Rivero-Ayerza M, Scholte Op Reimer W, Lenzen M, Theuns DA, Jordaens L, Komajda M, Follath F, Swedberg K, Cleland JG.

Eur Heart J. 2008 Jul;29(13):1618-24. doi: 10.1093/eurheartj/ehn217. Epub 2008 May 31.

34.

Can we believe in levosimendan?

Follath F.

Arq Bras Cardiol. 2008 Mar;90(3):146-7. English, Portuguese. No abstract available.

35.

Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level.

Stadler K, Ha HR, Ciminale V, Spirli C, Saletti G, Schiavon M, Bruttomesso D, Bigler L, Follath F, Pettenazzo A, Baritussio A.

Am J Respir Cell Mol Biol. 2008 Aug;39(2):142-9. doi: 10.1165/rcmb.2007-0217OC. Epub 2008 Feb 28.

PMID:
18314540
36.

Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II.

Nieminen MS, Harjola VP, Hochadel M, Drexler H, Komajda M, Brutsaert D, Dickstein K, Ponikowski P, Tavazzi L, Follath F, Lopez-Sendon JL.

Eur J Heart Fail. 2008 Feb;10(2):140-8. doi: 10.1016/j.ejheart.2007.12.012.

37.

Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes.

Mebazaa A, Gheorghiade M, Piña IL, Harjola VP, Hollenberg SM, Follath F, Rhodes A, Plaisance P, Roland E, Nieminen M, Komajda M, Parkhomenko A, Masip J, Zannad F, Filippatos G.

Crit Care Med. 2008 Jan;36(1 Suppl):S129-39. doi: 10.1097/01.CCM.0000296274.51933.4C. Review.

PMID:
18158472
38.

Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition.

Zannad F, Stough WG, Pitt B, Cleland JG, Adams KF, Geller NL, Torp-Pedersen C, Kirwan BA, Follath F.

Eur Heart J. 2008 Feb;29(3):413-21. doi: 10.1093/eurheartj/ehm603.

39.

Recall of lifestyle advice in patients recently hospitalised with heart failure: a EuroHeart Failure Survey analysis.

Lainscak M, Cleland JG, Lenzen MJ, Nabb S, Keber I, Follath F, Komajda M, Swedberg K.

Eur J Heart Fail. 2007 Nov;9(11):1095-103. Epub 2007 Sep 20.

40.

Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.

Borer JS, Pouleur H, Abadie E, Follath F, Wittes J, Pfeffer MA, Pitt B, Zannad F.

Eur Heart J. 2007 Aug;28(15):1904-9. Epub 2007 Jul 5. Review.

41.

Management of patients with heart failure in clinical practice: differences between men and women.

Lenzen MJ, Rosengren A, Scholte op Reimer WJ, Follath F, Boersma E, Simoons ML, Cleland JG, Komajda M.

Heart. 2008 Mar;94(3):e10. Epub 2007 Jun 17.

PMID:
17575332
42.

Nonpharmacologic measures and drug compliance in patients with heart failure: data from the EuroHeart Failure Survey.

Lainscak M, Cleland JG, Lenzen MJ, Keber I, Goode K, Follath F, Komajda M, Swedberg K.

Am J Cardiol. 2007 Mar 26;99(6B):31D-37D. Epub 2007 Jan 25.

PMID:
17378994
43.

Synthesis and cytotoxicity properties of amiodarone analogues.

Bigler L, Spirli C, Fiorotto R, Pettenazzo A, Duner E, Baritussio A, Follath F, Ha HR.

Eur J Med Chem. 2007 Jun;42(6):861-7. Epub 2007 Jan 14.

PMID:
17316909
44.

Electrocardiographic artifacts due to electrode misplacement and their frequency in different clinical settings.

Rudiger A, Hellermann JP, Mukherjee R, Follath F, Turina J.

Am J Emerg Med. 2007 Feb;25(2):174-8.

PMID:
17276807
45.

Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge.

Khan NK, Goode KM, Cleland JG, Rigby AS, Freemantle N, Eastaugh J, Clark AL, de Silva R, Calvert MJ, Swedberg K, Komajda M, Mareev V, Follath F; EuroHeart Failure Survey Investigators.

Eur J Heart Fail. 2007 May;9(5):491-501. Epub 2007 Jan 9.

46.

Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I.

Komajda M, Hanon O, Hochadel M, Follath F, Swedberg K, Gitt A, Cleland JG.

Eur Heart J. 2007 Jun;28(11):1310-8. Epub 2006 Dec 21.

PMID:
17185303
47.

[Current insights into the modern treatment of decompensated heart failure].

Vilas-Boas F, Follath F.

Arq Bras Cardiol. 2006 Sep;87(3):369-77. Review. English, Portuguese.

48.

International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey.

Lainscak M, Cleland JG, Lenzen MJ, Follath F, Komajda M, Swedberg K.

Eur J Heart Fail. 2007 Mar;9(3):292-9. Epub 2006 Oct 4.

49.

EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population.

Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L; EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology.

Eur Heart J. 2006 Nov;27(22):2725-36. Epub 2006 Sep 25.

PMID:
17000631
50.

Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives.

Waldhauser KM, Török M, Ha HR, Thomet U, Konrad D, Brecht K, Follath F, Krähenbühl S.

J Pharmacol Exp Ther. 2006 Dec;319(3):1413-23. Epub 2006 Sep 13.

PMID:
16971508

Supplemental Content

Loading ...
Support Center